JPMorgan Downgrades ZIOPHARM Oncology (ZIOP) to Underweight
Tweet
Share
E-mail
Get Alerts ZIOP Hot Sheet
Price: $0.87 --0%
Rating Summary:
6 Buy, 9 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
6 Buy, 9 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
JPMorgan downgraded ZIOPHARM Oncology (NASDAQ: ZIOP) from Neutral to Underweight.
Analyst Eric Joseph is negative on the company citing pipeline skepticism and cash overhang as focus points following the FDA clinical hold on the company's Phase 1 study to evaluate point of care CD19 CAR-T program for lymphoma/leukemia.
For an analyst ratings summary and ratings history on ZIOPHARM Oncology click here. For more ratings news on ZIOPHARM Oncology click here.
Shares of ZIOPHARM Oncology closed at $4.30 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
- Beike (BEKE) PT Raised to $23 at Morgan Stanley
- Walmart (WMT) PT Lowered to $125 at JPMorgan, Overweight Rating Maintained as 'Short Case Feels Greedy'
Create E-mail Alert Related Categories
Analyst Comments, Downgrades, Hot DowngradesRelated Entities
JPMorgan, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
